Diabetic retinopathy: A clinical update

Diabetologia

Volumn 45, Issue 12, 2002, Pages 1617-1634

  Porta, Massimo ^a   Bandello, F ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Blindness; Blood glucose; Blood pressure; Diabetes; Diabetic retinopathy; Laser photocoagulation; Metabolic control

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; LISINOPRIL; SORBINIL; TICLOPIDINE;

BLINDNESS; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE COURSE; EYE FUNDUS; GLUCOSE BLOOD LEVEL; HEALTH CARE SYSTEM; HUMAN; INDUSTRIALIZATION; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; LOW LEVEL LASER THERAPY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OCULAR FIBROSIS; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; RISK FACTOR; SCOTOMA; SCREENING; SURVIVAL; VISUAL IMPAIRMENT; VITRECTOMY; ANIMAL; CLASSIFICATION; METHODOLOGY; VISION TEST;

ANIMALS; BLINDNESS; DIABETIC RETINOPATHY; HUMANS; PREVALENCE; RISK FACTORS; VISION SCREENING;

EID: 0036460325     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-002-0990-7     Document Type: Review

References (156)

1. Klein R, Klein BEK, Jensen SC, Moss SE (1994) The relation of socioeconomics factors to the incidence of proliferative diabetic retinopathy and loss of vision. Ophthalmology 101: 68-76
2. Kuh D, Lawrence C, Tripp J, Creber G (1988) Work and work alternative for disabled young people. Disabil Handicap Soc 3: 3-26
3. Chiang YP, Bassi LJ, Javitt JC (1992) Federal budgetary costs of blindness. Milbank Q 70: 319-340
4. King H, Aubert RE, Herman WH (1988) Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21: 1414-1431
5. Klein R, Klein BEK, Moss SE (1984) Prevalence of diabetes mellitus in Southern Wisconsin. Am J Epidemiol 119: 54-61
6. Stephenson J, Fuller JH and the EURODIAB IDDM Complications Study Group (1994) Microvascular and acute complications in IDDM patients: The EURODIAB IDDM Complications Study. Diabetologia 37: 278-285
7. Malone JI, Pavan PR, Morrison AD, Cuthbertson DD (2001) Prevalence and significance of retinopathy in subjects with type 1 diabetes and less than 5 years' duration screened for the Diabetes Control and Complications Trial. Diabetes Care 24: 522-526
8. Kernell A, Dedorsson I, Johansson B et al. (1997) Prevalence of diabetic retinopathy in children and adolescents with IDDM. A population-based multicentre study. Diabetologia 40: 307-310
9. Krolewski AS, Warram JH, Rand LI, Christlieb AR, Busick EJ, Kahn CR (1986) Risk of proliferative diabetic retinopathy in juvenile-onset type I diabetes: A 40-yr follow-up study. Diabetes Care 9: 443-452
10. Palmberg P, Smith M, Waltman S et al. (1981) The natural history of retinopathy in insulin-dependent juvenile-onset diabetes. Ophthalmology 88: 613-618
11. Harris MI, Klein R, Welborn TA, Knuiman MW (1992) Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15: 815-819
12. UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853
13. Kohner EM, Porta M (1990) Diabetic retinopathy. In: Alberti KGMM, Krall LP (eds) The diabetes annual, 5th edn. Elsevier, Amsterdam, pp 273-300
14. Klein R, Klein BEK, Moss SE, Cruickshanks KJ (1995) The Wisconsin Epidemiologic Study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 102: 7-16
15. The Diabetes Control and Complications Trial (DCCT) Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 329: 977-986
16. Cruickshanks KJ, Ritter LL, Klein R, Moss SE (1993) The association of microalbuminuria with diabetic retinopathy. The Wisconsin Epidemiologic Study of diabetic retinopathy. Ophthalmology 100: 862-867
17. Moss SE, Klein R, Klein BEK (1994) Ocular factors in the incidence and progression of diabetic retinopathy. Ophthalmology 101: 77-83
18. Klein R, Meuer SM, Moss SE, Klein BEK (1995) Retinal microaneurysm counts and 10-year progression of diabetic retinopathy. Arch Ophthalmol 113: 1386-1391
19. Chaturvedi N, Sjoelie AK, Porta M et al. (2001) Markers of insulin resistance are strong risk factors for the incidence of retinopathy in type 1 diabetes: Findings from the EURODIAB PCS. Diabetes Care 24: 284-289
20. Chew EY, Klein ML, Ferris FL et al. (1996) Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) report 22. Arch Ophthalmol 114:1079-1084
21. Moss SE, Klein R, Klein BEK (1994) The association of alcohol consumption with the incidence and progression of diabetic retinopathy. Ophthalmology 101: 1962-1968
22. Moss SE, Klein R, Klein BEK (1991) Association of cigarette smoking with diabetic retinopathy. Diabetes Care 14: 119-126
23. Stratton I, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR for the UKPDS Group (2001) UKPDS 50: Risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44: 156-163
24. Porta M, Sjolie A-K, Chaturvedi N et al. (2001) Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB prospective complications study. Diabetologia 44: 2203-2209
25. Moss SE, Klein R, Klein BEK (1994) Ten-year incidence of visual loss in a diabetic population. Ophthalmology 101: 1061-1070
26. Aiello LP, Cahill MT, Wong JS (2001) Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 132: 760-776
27. Zhang LY, Krzentowski G, Albert A, Lefevbre PJ (2001) Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 24: 1275-1279
28. Herman WH, Teutsch SM, Sepe SJ, Sinnock P, Klein R (1983) An approach to the prevention of blindness in diabetes. Diabetes Care 6: 608-613
29. American Diabetes Association. (1997) Position Statement Screening for diabetic retinopathy. Diabetes Care 20 [Suppl 1]: S28-S30
30. Moss SE, Klein R, Klein BEK (1998) The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105: 998-1003
31. Ghafour IM, Allan D, Foulds WS (1983) Common causes of blindness and visual handicap in the West of Scotland. Br J Ophthalmol 67: 209-213
32. Grey RHB, Malcolm N, O' Reilly D, Morris M (1986) Ophthalmic survey of a diabetic clinic. I: Ocular findings. Br J Ophthalmol 70: 797-803
33. Sjolie A-K, Green A (1987) Blindness in insulin-treated diabetic patients with age at onset <30 years. J Chronic Dis 40: 215-220
34. Porta M, Tomalino MG, Santoro F, et al. (1995) Diabetic retinopathy as a cause of blindness in the province of Turin, North-West Italy, in 1967-1991. Diab Med 12: 355-361
35. Trautner C, Haastert B, Giani G, Berger M (2001) Incidence of blindness in southern Germany between 1990 and 1998. Diabetologia 44: 147-150
36. Witkin SR, Klein R (1984) Ophthalmic care for persons with diabetes. JAMA 251: 2534-2537
37. Brechner RJ, Cowle CC, Howie LJ, Herman WH, Will JC, Harris MI (1993) Ophthalmic examination among adults with diagnosed diabetes mellitus. JAMA 270: 1714-1718
38. Jones RB, Laritzgoitia I, Casado L, Barrie T (1989) How effective is the referral chain for diabetic retinopathy? Diabet Med 6: 262-266
39. Klein R, Klein BEK, Jensen SC, Moss SE (1994) The relation of socio-economic factors to the incidence of proliferative diabetic retinopathy and loss of vision. Ophthalmology 101: 68-76
40. Chaturvedi N, Stephenson JM, Fuller JH and the EURODIAB IDDM Complications Study Group (1996) The relationship between socioeconomic status and diabetes control and complications in the EURODIAB IDDM Complications Study. Diabetes Care 19: 423-430
41. Davis MD, Norton EWD, Myers FL (1969) The Airlie House classification of diabetic retinopathy. In: Goldberg MF, Fine SL (eds) Symposium on the Treatment of Diabetic Retinopathy. PHS Pub No 1890, Washington DC
42. Diabetic Retinopathy Study Research Group (1979) DRS report no 3. Four risk factors for severe visual loss in diabetic retinopathy. Arch Ophthalmol 97: 654-655
43. Early Treatment Diabetic Retinopathy Study Research Group (1991) Grading diabetic retinopathy from stereoscopic colour fundus photographs - An extension of the modified Airlie House classification. ETDRS report no 10. Ophthalmology 98: 786-806
44. Early Treatment Diabetic Retinopathy Study Research Group (1991) Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report no 12. Ophthalmology 98: 823-833
45. Lattanzio R, Brancato R, Bandello F et al. (2001) Florid diabetic retinopathy (FDR): A long term follow-up study. Graefes Arch Clin Exp Ophthalmol 239: 182-187
46. Appen RE, Chandra SR, Klein R et al. (1980) Diabetic papillopathy. Am J Ophthalmol 90: 203-209
47. Brancato R, Menchini U, Bandello F (1986) Diabetic papillopathy: Fluorangiographic aspects. Metab Pediatr Syst Ophthalmol 9: 57-61
48. Early Treatment Diabetic Retinopathy Study Research Group (1991) Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report no 11. Ophthalmology 98: 807-822
49. Hee MR, Puliafito CA, Duker JS et al. (1998) Topography of diabetic macular oedema with optical coherence tomography. Ophthalmology 105: 360-370
50. Bandello F, Brancato R, Lattanzio R, Falcomata B, Malegori A (1993) Biomicroscopy versus fluorescein angiography of the iris in the detection of diabetic iridopathy. Graefes Arch Clin Exp Ophthalmol 231: 444-448
51. Pirart J (1977) Diabète et complications dégénératives. Présentation d'une étude prospective portant sur 4400 cas observés entre 1947 et 1973. Diabetes Metab 1: 97-107; 173-182; 245-256
52. Krolewski AS, Warram JH, Rand LI, Kahn CR (1987) Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med 317: 1390-1398
53. Stephenson JM, Fuller JH, Viberti GC, Sjolie A-K, Navalesi R, the EURODIAB IDDM Complications Study Group (1995) Blood pressure, retinopathy and urinary albumin excretion in IDDM: The EURODIAB IDDM Complications Study. Diabetologia 38: 599-603
54. Grenfell A, Watkins PJ (1986) Clinical diabetic nephropathy. Natural history and complications. Clin Endocrinol Metab 15: 783-805
55. Parving H-H, Hommel E, Mathiesen E, et al. (1988) Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin-dependent diabetes. BMJ 296: 156-160
56. Feldman JN, Hirsch SR, Beyer MB, et al. (1982) Prevalence of diabetic nephropathy at time of treatment for diabetic retinopthy. In: Friedman EA, L'Esperance FA (eds) Diabetic Renal-Retinal Syndrome, vol 2. Grune and Stratton, New York, pp 9-20
57. Parving H-H, Gall M-A, Skott P et al. (1990) Prevalence and causes of albuminuria in non-insulin dependent diabetic NIDDM patients. Kidney Int 37: 243
58. Schmitz A, Vaeth M (1988) Microalbuminuria: A major risk factor in non-insulin dependent diabetes. A 10-year follow-up study of 503 patients. Diabet Med 5: 126-134
59. Joint Working Party on Diabetic Renal Failure (1989) Treatment and mortality of diabetic renal failure patients identified in the 1985 UK survey. BMJ 299: 1135-1136
60. Klein BEK, Moss SE, Klein R (1990) Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 13: 34-40
61. Bandello F, Brancato R, Lattanzio R et al. (1997) Evolution of initial retinal microangiopahy in pregnant diabetic women. Invest Ophthalmol Vis Sci 38: 1120S
62. The DCCT research Group (2000) Effect of pregnancy on microvascular complications in the DCCT. Diabetes Care 23: 1084-1091
63. Kohner EM, Porta M (1993) Screening for Diabetic Retinopathy in Europe: A Field Guide-Book. World Health Organization, Regional Office for Europe, Copenhagen, pp 1-51
64. Gibbins RL, Owens DR, Allen JC, Eastman L (1998) Practical application of the European Field Guide in screening retinopathy by using ophthalmoscopy and 35 mm retinal slides. Diabetologia 41: 59-64
65. Javitt JC, Aiello LP, Bassi LJ, Chiang YP, Canner JK (1991) Detecting and treating retinopathy in patients with type I diabetes mellitus. Ophthalmology 98: 1565-1574
66. Hutchinson A, McIntosh A, Peters J et al. (2000) Effectiveness of screening and monitoring tests for diabetic retinopathy. Diabet Med 17: 495-506
67. Bursell SE, Cavallerano JD, Cavallerano AA et al. (2001) Stereo nonmydriatic digital-video retinal imaging compared with Early Treatment Diabetic Retinopathy Study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy. Ophthalmology 108: 572-585
68. Liesenfeldt B, Bek T, Kohner E et al. (2000) A telemedical approach to the screening of diabetic retinopathy: Digital fundus photography. Diabetes Care 23: 345-348
69. Gardner GG, Keating D, Williamson TH, Elliott AT (1996) Automatic detection of diabetic retinopathy using an artificial neural network: A screening tool. Br J Ophthalmol 80: 940-944
70. Sinthanayothin C, Boyce JF, Williamson TH et al. (2002) Automated detection of diabetic retinopathy on digital fundus images. Diabetic Med 19: 105-112
71. Stefansson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E (2000) Screening and prevention of diabetic blindness. Acta Ophthalmol Scand 78: 374-385
72. Backlund LB, Algvere PV, Rosenqvist U (1994) New blindness in diabetes reduced by more than one-third in Stockholm County. Diabet Med 14: 732-740
73. Hansson-Lundblad C, Holm K, Agardh CD, Agardh E (2002) A small number of older type 2 diabetic patients end up visually impaired despite regular photographic screening and laser treatment for diabetic retinopathy. Acta Ophthalmol Scand 80: 310-315
74. Javitt JC, Aiello LP (1996) Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 124: 164-169
75. Porta M, Rizzitiello A, Tomalino M et al. (1999) A comparison of the cost-effectiveness of three approaches to screen for sight-threatening diabetic retinopathy. Diabet Metab 25: 44-53
76. Laupacis A, Feeny D, Detsky AS, Tugwell PX (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146: 473-481
77. Trento M, Bajardi M, Borgo E et al. (2002) Perceptions of diabetic retinopathy and screening procedures among diabetic people. Diabet Med 19: 810-813
78. Trento M, Passera P, Tomalino M et al. (2001) Group visits improve metabolic control in type 2 diabetes. Diabetes Care 24: 995-1000
79. Trento M, Passera P, Bajardi M et al. (2002) Lifestyle intervention by group care prevents deterioration of type II diabetes: A 4-year randomized controlled clinical trial. Diabetologia 45: 1231-1239
80. Clark CM, Lee DA (1995) Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 332: 1210-1217
81. Ferris FL, Davis MD, Aiello LM (1999) Treatment of diabetic retinopathy. N Engl J Med 341: 667-678
82. Klein R, Klein BEK, Moss SE, Cruickshanks KJ (1998) The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-yr incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 105: 1801-1815
83. Kroc Collaborative Study Group (1984) Blood glucose control and the evolution of diabetic retinopathy and albuminuria: A preliminary multicenter trial. N Engl J Med 311: 365-372
84. Lauritzen T, Frost-Larsen K, Larsen H-W, Deckert T (1985) Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes 34 [Suppl 1]: 74-79
85. Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF, Sandvik L (1988) The response of diabetic retinopathy to 41 months of multiple insulin injections, insulin pumps and conventional insulin therapy. Arch Ophthalmol 106: 1242-1246
86. Reichard P, Nilsson B-Y, Rosenqvist U (1993) The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329: 304-309
87. The Diabetes Control and Complications Trial Research Group (1996) Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 276: 1409-1415
88. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a rial of intensive therapy. N Engl J Med 342: 381-389
89. The Diabetes Control and Complications Trial Research Group (1998) Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116: 874-886
90. Tovi J, Ingemansson SO, Engfeldt P (1998) Insulin treatment of elderly type 2 diabetic patients: Effects on retinopathy: Diabet Metab 24: 442-447
91. Grunwald JE, Riva CE, Petrig BL (1995) Strict control of glycaemia: Effects on blood flow in the large retinal vessels and in the macular microcirculation. Br J Ophthalmol 79: 735-741
92. Chantelau E, Kohner EM (1997) Why some cases of retinopathy worsen when diabetic control improves. BMJ 315: 1105-1106
93. Poulaki V, Qin W, Joussen AM et al. (2002) Acute intensive insulin therapy exacerbates diabetic blood retinal barrier breakdown via hypoxia-inducible factor 1-alpha and VEGF. J Clin Invest 109: 805-815
94. UKPDS Group (1998b) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-713
95. Suzuma I, Hata Y, Rook SL et al. (2001) Cyclic stretch and hypertension induced retinal VEGF-R2 (KDR) expression: Potential mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes 50: 444-454
96. Rassam SM, Patel V, Kohner EM (1995) The effect of experimental hypertension on retinal vascular autoregulation in humans: A mechanism for the progression of diabetic retinopathy. Exp Physiol 80: 53-68
97. Chaturvedi N, Sjolie AK, Stephenson JM, et al. (1998) Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 35: 28-31
98. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in hight-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) study investigators. N Engl J Med 342: 145-153
99. Estacio RO, Jeffers BW, Gifford N, Schrier RW (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23 [Suppl 2]: B54-B64
100. Wakisaka M, Yoshinari M, Nakamura S et al. (1999) Suppression of sodium-dependent glucose uptake by captopril improves high-glucose induced morphological and functional changes of cultured bovine retinal pericytes. Microvasc Res 58: 215-223
101. Gilbert RE, Kelly DJ, Cox AJ et al. (2000) Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 43: 1360-1367
102. Lonchampt M, Pennel L, Duhault J (2001) Hyperoxia/normoxia-driven retinal angiogenesis in mice: A role for angiotensin II. Invest Ophthalmol Vis Sci 42: 429-432
103. Poulsen JD (1953) Diabetes and anterior pituitary deficiency. Diabetes 2: 7-12
104. Lundbaek K, Christensen NJ, Jensen VA, et al. (1970) Diabetes, diabetic angiopathy and growth hormone. Lancet ii: 131-133
105. Salardi S, Cacciari E, Ballardini D et al. (1986) Relationships between growth factors (somatomedin-C and growth hormone) and body development, metabolic control, and retinal changes in children and adolescents with IDDM. Diabetes 35: 832-836
106. Janssen JAMJL, Lamberts SWJ (2000) Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol (Oxf) 52: 1-9
107. Sharp PS, Fallon TJ, Brazier OJ, Sandler L, Joplin JF, Kohner EM (1987) Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 30: 199-207
108. Mallet B, Vialettes B, Haroche S et al. (1992) Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabet Metab 18: 438-444
109. Grant MB, Cooper-DeHoff R, Mames RN et al. (2000) The efficacy of octreotide in the therapy of severe non-proliferative and early proliferative diabetic retinopathy. A randomized controlled study. Diabetes Care 23: 504-509
110. Idris I, Gray YS, Donnelly R (2001) Protein kinase C activation: Isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 44: 659-673
111. Aiello LP, Bursell SE, Clermont A et al. (1997) Vascular endothelial growth factor-induced permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46: 1473-1480
112. Sorbinil Retinopathy Trial Research Group (1990) A randomized trial of Sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 108: 1234-1244
113. The DAMAD Study Group (1989) Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicentre randomized controlled clinical trial. Diabetes 38: 491-498
114. The TIMAD Study Group (1990) Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 108: 1577-1583
115. Early Treatment of Diabetic Retinopathy Study Group (1991) Effects of aspirin treatment of diabetic retinopathy. ETDRS report no. 8. Ophthalmology 98: 757-765
116. Hammes HP, Martin S, Federlin K (1992) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88: 11555-11558
117. Kern TS, Engerman RL (2001) Pharmacological inhibition of diabetic retinopathy. Aminoguanidine and aspirin. Diabetes 50: 1636-1642
118. Diabetic Retinopaty Study Research Group (1978) Photocoagulation treatment of proliferative diabetic retinopathy: The second report of DRS findings. Ophthalmology 85: 82-106
119. Early Treatment Diabetic Retinopathy Study Research Group (1991) Early photocoagulation for diabetic retinopathy. ETDRS report No. 9. Ophthalmology 98: 766-785
120. Diabetes Control and Complications Trial (DCCT) Research Group (1987) Color photography versus fluorescein angiography in the detection of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 105: 1344-1351
121. Early Treatment Diabetic Retinopathy Study Research Group (1991) Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98: 823-833
122. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie A, The EURODIAB IDDM Complications Study Group (1995) Methodology for retinal photography and assessment of diabetic retinopathy: The EURODIAB IDDM Complications Study. Diabetologia 38: 437-444
123. Early Treatment Diabetic Retinopathy Study Research Group (1987) Treatment techniques and clinical guidelines for photocoagulation and diabetic macular edema. ETDRS report no 2. Ophthalmology 94: 761-764
124. Bandello F (2001) Fluorescein angiography in laser treatment of diabetic macular edema. Ophthalmology 108: 236
125. Abu el-Asrar A, Morse PH (1991) Laser photocoagulation control of diabetic macular oedema without fluorescein angiography. Br J Ophthalmol 75: 97-99
126. The Diabetes Control and Complications Trial Research Group (1995) The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol 113: 36-51
127. Schatz H, Madeira D, McDonald R, Johnson RN (1997) Progressive enlargement of laser scars following grid laser photocoagulation for diffuse macular edema. Arch Ophthalmol 109: 1549-1551
128. Lee CM, Olk RJ (1991) Modified grid laser photocoagulation for diffuse diabetic macular edema: Long term visual results. Ophthalmology 98: 1594-1602
129. Lewis H, Schachat AP, Haimann MH et al. (1990) Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 97: 503-510
130. Han DP, Mieler WF, Burton TC (1992) Submacular fibrosis after photocoagulation for diabetic macular edema. Am J Ophthalmol 113: 513-521
131. Guyer DR, D'Amico DJ, Smith CW (1992) Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol 113: 652-656
132. Fong DS, Segal PP, Myers FL, Ferris FL, Hubbard LD, Davis MD (1997) Subretinal fibrosis in diabetic macular edema. ETDRS report no. 23. Arch Ophthalmol 115: 873-887
133. Doft BH, Blankenship G (1982) Single versus multiple treatment sessions of argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 89: 772-779
134. Doft BH, Blankenship G (1984) Retinopathy risk factor regression after laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 91:1453-1457
135. Vine AK (1985) The efficacy of additional argon laser photocoagulation for persistent, severe proliferative diabetic retinopathy. Ophthalmology 92: 1532-1537
136. Aiello LP, Avery RL, Arrigg PG et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487
137. Stefansson E, Machemer R, deJuan E, McCuen BW, Peterson J (1992) Retinal oxygenation and laser treatment in patients with diabetic retinopathy. Am J Ophthalmol 113: 36-38
138. Glaser BM, Campochiaro PA, Davis JL, Sato M (1985) Retinal pigment epithelial cells release an inhibitor of neovascularization. Arch Ophthalmol 103: 1870-1875
139. Spranger J, Hammes H-P, Preissner KT, Schatz H, Pfeiffer AFH (2000) Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: Association with retinal photocoagulation. Diabetologia 43: 1404-1407
140. Ferris FL, Podgor MJ, Davis MD (1987) Macular edema in Diabetic Retinopathy Study patients. DRS report no. 12. Ophthalmology 94: 754-760
141. McDonald HR, Schatz H (1985) Macular edema following panretinal photocoagulation Retina 5: 5-10
142. Gardner TW, Eller AW, Friberg TR (1990) Reduction of severe macular edema in eyes with poor vision after pan-retinal photocoagulation for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 229: 323-328
143. Elliott A, Flanagan D (1990) Macular detachment following laser treatment for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 228: 438-441
144. Hamilton AM, Townsend C, Khoury D, Gould E, Blach RK (1981) Xenon arc and argon laser photocoagulation in the treatment of diabetic disc neovascularization. I. Effect on disc vessels, visual field and visual acuity. Trans Ophthalmol Soc UK 101: 87-92
145. Pender PM, Benson WE, Compton H, Cox GB (1981) The effects of panretinal photocoagulation on dark adaptation in diabetics with proliferative retinopathy. Ophthalmology 88: 635-638
146. Diabetic Retinopathy Vitrectomy Study Research Group (1985) Early vitrectomy for severe vitreous haemorrhage in diabetic retinopathy. Two-year results of a randomized trial. DRVS report no 2. Arch Ophthalmol 103: 1644-1652
147. Smiddy WE, Flynn HW (1999) Vitrectomy in the management of diabetic retinopathy. Surv Ophthalmol 43: 491-507
148. Diabetic Retinopathy Vitrectomy Study Research Group (1990) Early vitrectomy for severe vitreous haemorrhage in diabetic retinopathy: Four year results of a randomized trial. DVRS report no. 5. Arch Ophthalmol 108: 958-964
149. Diabetic Retinopathy Vitrectomy Study Research Group (1988) Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial. DRVS Report No 4. Ophthalmology 95: 1321-1324
150. Rice TA, Michels RG, Rice EF (1983) Vitrectomy for diabetic rhegmatogenous retinal detachment. Am J Ophthalmol 95: 34-44
151. Nasrallah FP, Jalkh AE, van Coppenolle F et al. (1988) The role of the vitreous in diabetic macular edema. Ophthalmology 95: 1335-1339
152. Hikichi T, Fujio N, Akiba J, Azuma Y, Takahashi M, Yoshida A (1997) Association between the short-term natural history of diabetic macular edema and the vitreo-macular relationship in type II diabetes mellitus. Ophthalmology 104: 473-478
153. Harbour JW, Smiddy WE, Flynn HW, Rubsamen PE (1996) Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 121: 405-413
154. Tachi N, Ogino N (1996) Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol 122: 258-260
155. Pendergast SD, Hassan TS, Williams GA et al. (2000) Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol. 130: 178-186
156. Yamamoto T, Akabane N, Takeuchi S (2001) Vitrectomy for diabetic macular edema: The role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 132: 369-377